Publications by authors named "Scott R Plotkin"

Claim this Profile
P
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant Glioma.
Gilbert Youssef, Elisa Aquilanti, Julie J Miller, Zhou Lan, Aleksandra B Lasica, Scott R Plotkin

Neuro Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectives.
Sophia C Carias, Frank D Buono, Liesel Von Imhof, Sneha M Yelamanchili, Hilary Chan, Scott R Plotkin

Fam Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas.
Christopher G Wood, Liana Kozanno, Anat Stemmer-Rachamimov, Daniel J Lee, Fred G Barker, Scott R Plotkin

Laryngoscope· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
Leon D Kaulen, Maria Martinez-Lage, Jeremy S Abramson, Philipp Karschnia, Sofia Doubrovinskaia, Scott R Plotkin

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical epidemiology of NF2-related schwannomatosis.
D Gareth Evans, Scott R Plotkin

Handb Clin Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical therapy for vestibular schwannoma.
D Gareth Evans, Scott R Plotkin

Handb Clin Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
History and clinical epidemiology of NF2-related schwannomatosis.
D Gareth Evans, Jaishri O Blakeley, Scott R Plotkin

Fam Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma.
J Erika Haydu, Robert A Redd, Matthew M Lei, Ephraim Hochberg, Jeffrey A Barnes, Scott R Plotkin

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab.
Shivani Ahlawat, Patrick Debs, Laura M Fayad, Scott R Plotkin, Brigitte C Widemann

J Neurooncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
Vihang Nakhate, Ina Ly, Alona Muzikansky, Otto Rapalino, Jeffrey C Allen, Scott R Plotkin

J Neurooncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
Rishab Ramapriyan, Fred G Barker, Leland G Richardson, Jing Sun, Gust Vandecandelaere, Scott R Plotkin

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Eva Dombi, Andrea M Gross, Brigitte C Widemann, Brian D Weiss, Scott R Plotkin

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.
L Nicolas Gonzalez Castro, Avishai Gavish, Lillian Bussema, Christopher W Mount, Cyril Neftel, Scott R Plotkin

Genome Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national survey.
Vanessa L Merker, Yidan Ma, Lori B Chibnik, Heather B Radtke, Kate Kelts, Scott R Plotkin

Orphanet J Rare Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.
Simeng Lu, Zhenzhen Yin, Limeng Wu, Yao Sun, Jie Chen, Scott R Plotkin

bioRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib.
Scott R Plotkin, Jaishri O Blakeley

Neuro Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Joe S Mendez, Adam L Cohen, Midori Eckenstein, Randy L Jensen, Lindsay M Burt, Scott R Plotkin

Neurooncol Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving concepts in meningioma management in the era of genomics.
Annie L Hsieh, Wenya Linda Bi, Vijaya Ramesh, Priscilla K Brastianos, Scott R Plotkin

Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to L. Lucchino et al. on commentary on "Histologic correlates of "Choroidal Abnormalities" in Neurofibromatosis type 1".
Anat O Stemmer-Rachamimov, Liana Kozanno, Scott R Plotkin, Justin T Jordan, Joseph F Rizzo

Acta Neuropathol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.
Shilpa Prabhakar, Roberta L Beauchamp, Pike See Cheah, Akiko Yoshinaga, Edwina Abou Haidar, Scott R Plotkin

Mol Ther Methods Clin Dev· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brigatinib in -Related Schwannomatosis with Progressive Tumors.
Scott R Plotkin, Kaleb H Yohay, Phioanh L Nghiemphu, Christine T Dinh, Dusica Babovic-Vuksanovic

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, Jahanbanoo Shahryari, John Kincaid, Scott R Plotkin

Sci Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Simeng Lu, Zhenzhen Yin, Jie Chen, Limeng Wu, Yao Sun, Scott R Plotkin

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1).
Anat O Stemmer-Rachamimov, Liana Kozanno, Scott R Plotkin, Justin T Jordan, Joseph F Rd Rizzo

Acta Neuropathol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in -deficient models.
Srirupa Bhattacharyya, Janet L Oblinger, Roberta L Beauchamp, Lili Kosa, Francis Robert, Scott R Plotkin

Neurooncol Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis